Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | FPR2 | P25090 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561333 | 0.86 | MET (0.60) | METAXLFPR2RAB9AROCK2 | |
| SCHEMBL20941583 | 0.85 | MET (0.54) | METAXLFPR2ROCK2ROCK1 | |
| SCHEMBL14817518 | 0.82 | MET (0.49) | METAXLFPR2ROCK2ROCK1 | |
| SCHEMBL14412000 | 0.81 | MET (0.60) | METAXLFPR2ROCK2ROCK1 | |
| SCHEMBL13101680 | 0.81 | MET (0.57) | METAXLFPR2ROCK2ROCK1 | |
| SCHEMBL13906079 | 0.79 | MET (0.57) | METAXLFPR2RAB9AEPHX2 | |
| SCHEMBL12536983 | 0.79 | MET (0.45) | METAXLFPR2LIPEMAPT | |
| SCHEMBL2605828 | 0.79 | MET (0.45) | METAXLFPR2ROCK2ROCK1 | |
| SCHEMBL16281036 | 0.79 | MET (0.45) | METAXLFPR2RAB9ALIPE | |
| SCHEMBL12536332 | 0.77 | HTT (0.44) | FPR2ROCK2ROCK1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731946-B2 | Broad spectrum antivirulence, anti-persistence compounds | ME2, ME1, ME3 | MET 3152/4885AXL 3197/4885FPR2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.